Clinical trial
Fulvestrant in Hormone Refractory Prostate Cancer
NCT00476645 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00476645 |
|---|---|
| Title | Fulvestrant in Hormone Refractory Prostate Cancer |
| Official title | Fulvestrant in Hormone-refractory Prostate Cancer |
| Lead sponsor | Stanford University, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms, Prostate Cancer |
| Intervention type | Drug |
| Interventions | Fulvestrant |
| Enrollment | 10 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | May 22, 2007 |
| Last update posted | Aug 5, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: